Helus Pharma's Phase 3 Success for HLP003 in MDD Signals Potential New Treatment Option

Helus Pharma's positive Phase 3 results for HLP003 in major depressive disorder demonstrate statistically significant and rapid improvements, potentially offering a new adjunctive treatment for this debilitating condition.

Chicago Metrowire Staff
••Healthcare
Helus Pharma's Phase 3 Success for HLP003 in MDD Signals Potential New Treatment Option

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced positive topline results from its pivotal Phase 3 APPROACH trial evaluating HLP003 (deuterated psilocin) as an adjunctive treatment for adults with major depressive disorder (MDD). The randomized, double-blind, placebo-controlled study enrolled 222 participants and met its primary, key secondary, and other secondary endpoints, marking a significant milestone in the development of novel treatments for depression.

At the primary six-week endpoint, HLP003 produced a 19.5-point reduction from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS), compared with 11.9 points for placebo, a statistically significant difference of 7.6 points (p<0.0001). Notably, improvements were observed as early as Day 2, and treatment benefits were maintained through Week 12, with a placebo-adjusted difference of 7.0 points (p<0.0001). The trial also showed significant improvements in response and remission rates; 50.9% of treated participants achieved remission at Week 6 compared with 18.2% receiving placebo. These results underscore the potential of HLP003 to provide rapid and durable relief for patients suffering from MDD.

The treatment was generally well tolerated, with most adverse events mild to moderate and transient. Three treatment-related serious adverse events were reported, but no new safety signals were identified. The positive safety profile, combined with the robust efficacy data, positions HLP003 as a promising candidate for regulatory approval.

The APPROACH trial is the first of three studies in the company's PARADIGM Phase 3 program, which also includes the ongoing EMBRACE pivotal trial and the EXTEND long-term extension study. Helus Pharma expects to report topline results from EMBRACE in the fourth quarter of 2027. These upcoming milestones are critical as the company advances HLP003 toward potential commercialization. For a detailed view of the press release, visit https://ibn.fm/IloYS.

Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs) to address large unmet needs in depression, anxiety, and other mental health conditions. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to offer a meaningful improvement over existing therapies. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com.

The announcement is being disseminated through NetworkNewsWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. NetworkNewsWire provides access to wire solutions via InvestorWire and offers editorial syndication to 5,000+ outlets, among other services. For full terms and disclaimers, see https://www.NetworkNewsWire.com/Disclaimer.

Blockchain Registration

QR Code for Blockchain Registration